ClinicalTrials.gg
Active, not recruitingNCT03671148KEEPsAKE2Updated Oct 28, 2026Results posted

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

A Phase 3 interventional study of Placebo and Risankizumab in Psoriatic Arthritis (PsA), sponsored by AbbVie. Active, not recruiting at 138 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Now Active, not recruitingStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Enrollment
4th of 11
444 · median 246
Started
2019
with 1 other
Phase 3
5 of 34
1 open now
Registered
24th of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 24th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).

Read the detailed description

The study consists of a Screening Period (approximately 35 days), Period 1, Period 2, and a 20-week Follow-up Period. Period 1 is a 24-week randomized, double-blind, placebo-controlled, parallel-group period. Period 2 is the long-term period and starts at Week 24. To maintain the blind to the original treatment allocation, treatment at the Week 24 Visit is blinded: participants randomized to placebo receive blinded risankizumab 150 mg, and participants randomized to risankizumab receive blinded placebo. At Week 28 and for the remaining dosing visits (to Week 316), all participants receive open-label risankizumab 150 mg every 12 weeks. Participants remain blinded to the original randomization allocation for the duration of the study. The total study duration is 336 weeks including a telephone call 140 days (20 weeks) after last dose of study drug.

03

Conditions studied

  • Psoriatic Arthritis (PsA)

Browse trials for

Keywords

  • KEEPsAKE 2
  • Risankizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at Screening Visit.
  • Participant has active disease defined as ≥ 5 tender joints (based on 68 joint counts) and ≥ 5 swollen joints (based on 66 joint counts) at both the Screening Visit and Baseline.
  • Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cm diameter or nail changes consistent with psoriasis at Screening Visit.
  • Participant has demonstrated an inadequate response or intolerance to biologic therapy(ies) or conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) therapy(ies).

Exclusion criteria

Exclusion Criteria:

  • Participant is considered by investigator, for any reason, to be an unsuitable candidate for the study.
  • Participant has a known to risankizumab.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
444 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

    Biological: Placebo · Biological: Risankizumab

  • Placebo comparator
    Placebo

    Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

    Biological: Placebo · Biological: Risankizumab

Interventions

  • BiologicalPlacebo

    Placebo for risankizumab administered by subcutaneous (SC) injection

  • BiologicalRisankizumab

    Risankizumab administered by subcutaneous (SC) injection

    Also known as: ABBV-066, BI 655066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline In Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24

    The Health Assessment Questionnaire Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 24

  2. Percentage Of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24

    PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from Baseline in PASI score.

    Time frame: Baseline and Week 24

  3. Percentage of Participants With an ACR20 Response at Week 16

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 16

  4. Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

    A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 15 (VAS from 0 to 100) * Patient's Global Assessment of disease activity ≤ 20 (VAS from 0 to 100) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, for an overall score range from 0 to 6)

    Time frame: Week 24

  5. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from Baseline score indicates improvement.

    Time frame: Baseline and Week 24

  6. Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 24

  7. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 24

  8. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 24

  9. Percentage of Participants With Resolution of Enthesitis at Week 24

    Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst).

    Time frame: Week 24

  10. Percentage of Participants With Resolution of Dactylitis at Week 24

    Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. The LDI basic is a score based on finger circumference and tenderness, assessed across all digits. The LDI basic measures the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot, using a minimum difference of 10% to define a dactylitic digit. The ratio of circumference is multiplied by a tenderness score (1 for tender, 0 for non-tender). If both sides of a digit are considered involved, or the circumference of the contralateral digit cannot be obtained, a standard reference table is used. Scores from each digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.

    Time frame: Week 24

07

Results

Posted Mar 2, 2022

Participant flow

Participants were enrolled at 99 sites in Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, France, Germany, Greece, Hungary, Israel, Italy, New Zealand, Poland, Portugal, South Africa, Spain, Sweden, United Kingdom, and the US including Puerto Rico. The study includes a 24-week double-blind placebo-controlled treatment period (Period 1) and an ongoing 184-week open-label treatment period (Period 2). Results are reported for Period 1 which was from 07 March 2019 to 22 June 2020.

Participant flow — Overall Study
MilestonePlaceboRisankizumab
Started220224
Received study drug219224
Completed199215
Not completed219
Withdrew: Adverse event32
Withdrew: Withdrawal by subject82
Withdrew: Lost to follow-up12
Withdrew: Lack of efficacy72
Withdrew: Covid-19 logistical restrictions01
Withdrew: Other10
Withdrew: Incomplete randomization visit10

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2426.5 (20.7 to 32.4)51.3 (44.8 to 57.9)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (A fixed sequence testing procedure is used to control the overall type I error rate at 2-sided alpha = 0.05 for the primary endpoint and ranked secondary endpoints.) · Response rate difference: 24.5 · 95% CI 15.9 to 33.0Response Rate Difference = Risankizumab - Placebo
SecondaryChange From Baseline In Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24

The Health Assessment Questionnaire Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline In Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline In Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24-0.05 (-0.12 to 0.02)-0.22 (-0.28 to -0.15)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = <0.001 (A fixed sequence testing procedure is used to control the overall type I error rate at 2-sided alpha = 0.05 for the primary endpoint and ranked secondary endpoints.) · Least squares (ls) mean difference: -0.16 · 95% CI -0.26 to -0.07Difference = Risankizumab - Placebo
SecondaryPercentage Of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from Baseline in PASI score.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage Of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage Of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 2410.2 (4.7 to 15.6)55.0 (46.2 to 63.9)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (A fixed sequence testing procedure is used to control the overall type I error rate at 2-sided alpha = 0.05 for the primary endpoint and ranked secondary endpoints.) · Response rate difference: 44.3 · 95% CI 33.9 to 54.6Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With an ACR20 Response at Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR20 Response at Week 16
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an ACR20 Response at Week 1625.3 (19.4 to 31.2)48.3 (41.7 to 54.8)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (A fixed sequence testing procedure is used to control the overall type I error rate at 2-sided alpha = 0.05 for the primary endpoint and ranked secondary endpoints.) · Response rate difference: 22.6 · 95% CI 13.9 to 31.2Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 15 (VAS from 0 to 100) * Patient's Global Assessment of disease activity ≤ 20 (VAS from 0 to 100) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, for an overall score range from 0 to 6)

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 2411.4 (7.2 to 15.6)25.6 (19.9 to 31.4)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (A fixed sequence testing procedure is used to control the overall type I error rate at 2-sided alpha = 0.05 for the primary endpoint and ranked secondary endpoints.) · Response rate difference: 14.0 · 95% CI 7.0 to 21.0Response Rate Difference = Risankizumab - Placebo
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from Baseline score indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 242.01 (0.94 to 3.08)5.87 (4.86 to 6.88)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = <0.001 (A fixed sequence testing procedure is used to control the overall type I error rate at 2-sided alpha = 0.05 for the primary endpoint and ranked secondary endpoints.) · Ls mean difference: 3.86 · 95% CI 2.41 to 5.31Difference = Risankizumab - Placebo
SecondaryChange From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 242.6 (1.4 to 3.9)4.9 (3.7 to 6.0)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = 0.009 (A fixed sequence testing procedure is used to control the overall type I error rate at 2-sided alpha = 0.05 for the primary endpoint and ranked secondary endpoints.) · Ls mean difference: 2.2 · 95% CI 0.6 to 3.9Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 249.3 (5.4 to 13.2)26.3 (20.3 to 32.3)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 16.6 · 95% CI 9.7 to 23.6Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 245.9 (2.7 to 9.0)12.0 (7.7 to 16.3)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = 0.024 · Response rate difference: 6.0 · 95% CI 0.8 to 11.3Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With Resolution of Enthesitis at Week 24

Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With Resolution of Enthesitis at Week 2430.4 (23.2 to 37.6)42.9 (34.9 to 50.9)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = 0.009 · Response rate difference: 13.8 · 95% CI 3.5 to 24.2Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With Resolution of Dactylitis at Week 24

Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. The LDI basic is a score based on finger circumference and tenderness, assessed across all digits. The LDI basic measures the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot, using a minimum difference of 10% to define a dactylitic digit. The ratio of circumference is multiplied by a tenderness score (1 for tender, 0 for non-tender). If both sides of a digit are considered involved, or the circumference of the contralateral digit cannot be obtained, a standard reference table is used. Scores from each digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With Resolution of Dactylitis at Week 2442.1 (29.3 to 54.9)72.5 (58.7 to 86.3)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 38.8 · 95% CI 22.9 to 54.8Response Rate Difference = Risankizumab - Placebo

Adverse events

Collected over From first dose of study drug to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/219 (0%)12/219 (5.5%)11/219 (5%)
Risankizumab 150 mg0/224 (0%)9/224 (4%)17/224 (7.6%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlaceboRisankizumab 150 mg
ANAEMIABlood and lymphatic system disorders1/2190/224
CARDIAC FAILURE CONGESTIVECardiac disorders1/2190/224
CORONARY ARTERY DISEASECardiac disorders1/2190/224
UMBILICAL HERNIAGastrointestinal disorders1/2190/224
ERYSIPELASInfections and infestations1/2190/224
GASTROENTERITISInfections and infestations1/2190/224
POSTOPERATIVE ABSCESSInfections and infestations1/2190/224
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/2190/224
URINARY TRACT INFECTIONInfections and infestations1/2190/224
FEMUR FRACTUREInjury, poisoning and procedural complications1/2190/224
Most frequent other events
Most frequent other events
EventPlaceboRisankizumab 150 mg
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations11/21917/224

Baseline characteristics

The full analysis set included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboRisankizumabTotal
Mean52.7 ± 12.6453.1 ± 12.5352.9 ± 12.57
Age, Customized
Age, Customized(Participants)PlaceboRisankizumabTotal
< 65 years176178354
≥ 65 years434689
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRisankizumabTotal
Female120124244
Male99100199
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRisankizumabTotal
Hispanic or Latino434285
Not Hispanic or Latino176182358
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRisankizumabTotal
White210218428
Black or African American325
Asian325
Multiple325
Current Use of Conventional Synthetic Disease-modifying Anti-rheumatic Drug (csDMARD)
Current Use of Conventional Synthetic Disease-modifying Anti-rheumatic Drug (csDMARD)(Participants)PlaceboRisankizumabTotal
Yes129141270
No9083173
Number of Prior Biologic Therapies
Number of Prior Biologic Therapies(Participants)PlaceboRisankizumabTotal
0 prior biologics118119237
≥ 1 prior biologic101105206
Extent of Psoriasis
Extent of Psoriasis(Participants)PlaceboRisankizumabTotal
< 3%100101201
≥ 3%119123242

12 further baseline measures are reported on the registry.

08

Study locations

138 sites
  • Pinnacle Research Group /ID# 167953
    Anniston, Alabama 36207, United States
  • St. Jude Heritage /ID# 166842
    Fullerton, California 92835, United States
  • Newport Huntington Medica /ID# 207423
    Huntington Beach, California 92648-5994, United States
  • Arthritis & Osteo Medical Ctr /ID# 166541
    La Palma, California 90623-1728, United States
  • East Bay Rheumatology Medical /ID# 166845
    San Leandro, California 94578, United States
  • Inland Rheum Clin Trials Inc. /ID# 166621
    Upland, California 91786, United States
  • Denver Arthritis Clinic /ID# 166442
    Denver, Colorado 80230, United States
  • New England Research Associates, LLC /ID# 166525
    Bridgeport, Connecticut 06606-1827, United States
  • Yale University /ID# 166330
    New Haven, Connecticut 06510, United States
  • Arthritis & Rheumatic Disease Specialties /ID# 212582
    Aventura, Florida 33180, United States
  • SIMED Health, LLC /ID# 207457
    Gainesville, Florida 32607-2817, United States
  • Sweet Hope Research Specialty Inc /ID# 168163
    Hialeah, Florida 33016-1897, United States
  • Rheum Assoc of Central FL /ID# 201629
    Orlando, Florida 32806, United States
  • HMD Research LLC /ID# 208428
    Orlando, Florida 32819, United States
  • Millennium Research /ID# 201627
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc. /ID# 208116
    Palm Harbor, Florida 34684, United States
  • IRIS Research and Development, LLC /ID# 166351
    Plantation, Florida 33324, United States
  • BayCare Medical Group /ID# 201630
    St. Petersburg, Florida 33705, United States
  • West Broward Rheumatology Associates /ID# 201234
    Tamarac, Florida 33321, United States
  • University of South Florida /ID# 208467
    Tampa, Florida 33612, United States
  • ForCare Clinical Research /ID# 166375
    Tampa, Florida 33613-1244, United States
  • Arthritis and Rheumatology /ID# 169438
    Atlanta, Georgia 30342, United States
  • Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 166681
    Skokie, Illinois 60076, United States
  • Springfield Clinic /ID# 166345
    Springfield, Illinois 62702-3749, United States
  • Ochsner Clinic Foundation /ID# 166622
    Baton Rouge, Louisiana 70836-6455, United States
  • The Arthritis & Diabetes Clinic, Inc. /ID# 166707
    Monroe, Louisiana 71203, United States
  • MMP Women's Health /ID# 169334
    Portland, Maine 04102, United States
  • Klein and Associates MD /ID# 166549
    Hagerstown, Maryland 21740, United States
  • Duplicate_The Center for Rheumatology & Bone Research /ID# 166448
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Gr /ID# 166455
    Worcester, Massachusetts 01605, United States
  • St. Paul Rheumatology /ID# 166599
    Eagan, Minnesota 55121, United States
  • Clinvest Research LLC /ID# 166745
    Springfield, Missouri 65810-2607, United States
  • Clayton Medical Associates, P.C. dba Saint Louis Rheumatology /ID# 166389
    St Louis, Missouri 63119-3845, United States
  • Glacier View Research Institute /ID# 169344
    Kalispell, Montana 59901, United States
  • Dartmouth-Hitchcock Medical Center /ID# 169443
    Lebanon, New Hampshire 03756, United States
  • Ocean Rheumatology, PA /ID# 166561
    Toms River, New Jersey 08755, United States
  • Arthritis Rheumatic and Back Disease Associates. P.A. /ID# 166658
    Voorhees Township, New Jersey 08043, United States
  • Paramount Medical Research Con /ID# 166334
    Middleburg Heights, Ohio 44130, United States
  • Health Research of Oklahoma /ID# 166408
    Oklahoma City, Oklahoma 73103-2400, United States
  • Altoona Ctr Clinical Res /ID# 166691
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Ctr Reading /ID# 166354
    Wyomissing, Pennsylvania 19610, United States
  • West Tennessee Research Institute /ID# 166429
    Jackson, Tennessee 38305, United States
  • Nashville Arthritis and Rheumatology /ID# 208395
    Nashville, Tennessee 37203, United States
  • Amarillo Ctr for Clin Research /ID# 208340
    Amarillo, Texas 79124, United States
  • Tekton Research, Inc. /ID# 166493
    Austin, Texas 78745, United States
  • Precision Comprehensive Clinical Research Solutions /ID# 208156
    Colleyville, Texas 76034, United States
  • Rheumatology Clinic of Houston /ID# 166636
    Houston, Texas 77065, United States
  • West Texas Clinical Research /ID# 208155
    Lubbock, Texas 79410-1198, United States
  • SW Rheumatology Res. LLC /ID# 166587
    Mesquite, Texas 75150, United States
  • Trinity Universal Research Associates, Inc /ID# 208387
    Plano, Texas 75024-5283, United States
  • DM Clinical Research /ID# 208350
    Tomball, Texas 77375, United States
  • Kadlec Clinic Rheumatology /ID# 167667
    Kennewick, Washington 99336, United States
  • Arthritis Northwest, PLLC /ID# 169535
    Spokane, Washington 99204-2302, United States
  • Rheumatology and Pulmonary Clinic /ID# 169341
    Beckley, West Virginia 25801, United States
  • Rheumatic Disease Center, LLP /ID# 166682
    Glendale, Wisconsin 53217, United States
  • Hospital General de Agudos J. M. Ramos Mejia /ID# 169152
    Buenos Aires, Ciuadad Autonoma de Buenos Aires 1221, Argentina
  • Hospital Italiano de Buenos Aires /ID# 208473
    Ciudad Autonoma Buenos Aires, Ciuadad Autonoma de Buenos Aires 1199, Argentina
  • DOM Centro de Reumatologia /ID# 208478
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1111, Argentina
  • Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 169151
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto CAICI /ID# 169156
    Rosario, Santa Fe Province 2000, Argentina
  • Centro Medico Privado de Reumatologia /ID# 208342
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Cimer /Id# 169155
    San Miguel de Tucumán, 4000, Argentina
  • The Canberra Hospital /ID# 207591
    Garran, Australian Capital Territory 2605, Australia
  • Rheumatology Research Unit Sunshine Coast /ID# 207191
    Maroochydore, Queensland 4558, Australia
  • Griffith University /ID# 207504
    Southport, Queensland 4222, Australia
  • Emeritus Research /ID# 207195
    Camberwell, Victoria 3124, Australia
  • Monash Medical Centre /ID# 208033
    Clayton, Victoria 3168, Australia
  • UZ Gent /ID# 210037
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Universitair Ziekenhuis Leuven /ID# 208209
    Leuven, Vlaams-Brabant 3000, Belgium
  • ReumaClinic /ID# 208211
    Genk, 3600, Belgium
  • ZNA - Jan Palfijn /ID# 208210
    Merksem, 2170, Belgium
  • CIP - Centro Internacional de Pesquisa /ID# 169524
    Goiânia, Goiás 74110-120, Brazil
  • LMK Sevicos Medicos S/S /ID# 169541
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Percuro Clinical Research, Ltd /ID# 169530
    Victoria, British Columbia V8V 3M9, Canada
  • CIADS Research Co Ltd /ID# 169526
    Winnipeg, Manitoba R3N 0K6, Canada
  • Dermatrials Research /ID# 208303
    Hamilton, Ontario L8N 1Y2, Canada
  • K. Papp Clinical Research /ID# 169527
    Waterloo, Ontario N2J 1C4, Canada
  • Centre Rhumatologie de l'Est /ID# 208302
    Rimouski, Quebec G5L 8W1, Canada
  • Bispebjerg and Frederiksberg Hospital /ID# 168763
    Frederiksberg, Capital Region 2000, Denmark
  • Aarhus University Hospital /ID# 168762
    Aarhus C, Central Jutland 8000, Denmark
  • East Tallinn Central Hospital /ID# 208317
    Tallinn, Harju 10138, Estonia
  • MediTrials /ID# 207815
    Tartu, Tartu 50708, Estonia
  • North Estonia Medical Centre /ID# 208319
    Tallinn, 13419, Estonia
  • Ite Pihlajanlinna Kuopio /ID# 208316
    Kuopio, 70100, Finland
  • Turku University Hospital /ID# 208199
    Turku, 20520, Finland
  • Duplicate_CHU Bordeaux-Hopital Pellegrin /ID# 211159
    Bordeaux, 33076, France
  • CHRU Tours - Hopital Trousseau /ID# 209343
    Chambray-lès-Tours, 37170, France
  • Rheumazentrum Ruhrgebiet /ID# 207212
    Herne, North Rhine-Westphalia 44649, Germany
  • Immanuel Krankenhaus Berlin /ID# 207214
    Buch, 13125, Germany
  • Center of Innovative Diagnostics and Therapeutics (CIRI GmbH) /ID# 209494
    Frankfurt, 60590, Germany
  • MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH /ID# 209493
    Hamburg, 20095, Germany
  • University General Hospital of Heraklion PA.G.N.I /ID# 206930
    Heraklion, Crete 71307, Greece
  • Naval Hospital of Athens /ID# 206928
    Athens, 11521, Greece
  • Olympion General Clinic SA /ID# 207047
    Pátrai, 26443, Greece
  • CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 169248
    Miskolc, Borsod-Abauj Zemplen county 3529, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 169237
    Szeged, Csongrád megye 6725, Hungary
  • Vital-Medicina Kft. /ID# 208123
    Veszprém, Veszprém megye 8200, Hungary
  • Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 209054
    Budapest, 1023, Hungary
  • Sheba Medical Center /ID# 207468
    Ramat Gan, Tel Aviv 5239424, Israel
  • Barzilai Medical Center /ID# 207471
    Ashkelon, 7830604, Israel

Showing the first 100 of 138 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Alperovich G, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Kivitz A. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022 Mar;81(3):351-358. doi: 10.1136/annrheumdis-2021-221048. Epub 2021 Nov 23. PubMed 34815219 ↗
  • Gossec L, Balanescu A, D'Agostino MA, Ogdie A, Sewerin P, Deng Y, Shi L, Sugimoto Y, Zhong S, Xing Y, Lippe R, Kishimoto M. Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naive patients in two phase 3 clinical trials. Arthritis Res Ther. 2025 Nov 29;28(1):2. doi: 10.1186/s13075-025-03670-0. PubMed 41318485 ↗
  • Ostor A, Van den Bosch F, Papp K, Keiserman M, Blanco R, Crowley A, White D, Biljan A, Madihlaba T, Carter K, Liu F, Soliman AM, Ashley D, Chen M, Glotfelty L, Kivitz A. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials. Rheumatol Ther. 2025 Dec;12(6):1103-1123. doi: 10.1007/s40744-025-00793-3. Epub 2025 Sep 30. PubMed 41028616 ↗
  • Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Oct;11(5):1403-1412. doi: 10.1007/s40744-024-00706-w. Epub 2024 Aug 9. PubMed 39120849 ↗
  • Kwatra SG, Khattri S, Amin AZ, Ranza R, Kaplan B, Shi L, Padilla B, Soliman AM, McGonagle D. Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials. Dermatol Ther (Heidelb). 2024 Jun;14(6):1517-1530. doi: 10.1007/s13555-024-01174-4. Epub 2024 May 13. PubMed 38739215 ↗
  • Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Carter K, Stakias V, Lippe R, Drogaris L, Soliman AM, Chen MM, Padilla B, Kivitz A. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatol Ther. 2024 Jun;11(3):633-648. doi: 10.1007/s40744-024-00657-2. Epub 2024 Mar 18. PubMed 38498139 ↗
  • Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Lu W, Wang Z, Soliman AM, Eldred A, Padilla B, Kivitz A. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatology (Oxford). 2023 Jun 1;62(6):2122-2129. doi: 10.1093/rheumatology/keac605. PubMed 36282537 ↗
  • Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30. PubMed 36178584 ↗
  • Ostor AJK, Soliman AM, Papp KA, Padilla B, Wang Z, Eldred A, de Vlam K, Kivitz A. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 2022 Jun;8(2):e002286. doi: 10.1136/rmdopen-2022-002286. PubMed 35701011 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jun 2020, 15 months.

Results were first posted in Mar 2022, 1 year 8 months after primary completion. A results delay was requested in Jun 2021.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2029, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2018
First posted
Sep 14, 2018
StartActual
Mar 7, 2019
Primary completionActual
Jun 22, 2020
CompletionEst.
Jan 2029was Jun 2026
Results delay requested
Jun 7, 2021
Results first posted
Mar 2, 2022
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Active, not recruiting
changed Oct 28, 2026
Study completion
Jun 4, 2026→Jan 2029
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Completed→Active, not recruiting
    Study completion Jun 4, 2026→Jan 2029
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03671148
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 14, 2018
Start date
Mar 7, 2019
Primary completion
Jun 22, 2020
Completion
Jan 2029 (estimated)
Results posted
Mar 2, 2022
Last update
Oct 28, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion